Pharma Pulse 6/11/25: Transforming Care for COPD; Pharmacists Provide Harm Reduction Services to Patients With Substance Use Disorder
Transforming Care for COPD: Q&A with Barry Quart
In an interview with Pharmaceutical Executive, Barry Quart, CEO, Connect Biopharma, discussed his decision to join the company to advance rademikibart—a novel biologic therapy showing promise in addressing the significant unmet need for effective treatments for acute exacerbations of asthma and COPD.
Pharmacists Provide Harm Reduction Services to Patients With Substance Use Disorder
A pharmacist recounts personal and professional experiences to highlight the urgent need for expanded harm reduction services—like syringe access and naloxone distribution—for patients with diabetes and substance use disorder, urging pharmacists to take a proactive role despite outdated laws and stigma.
Muhammad Cheema, PharmD, MPBA, reflects on the evolving role of pharmacy professionals in managing obesity, emphasizing how GLP-1 receptor agonists like semaglutide and liraglutide offer effective treatment options beyond lifestyle changes—and highlighting the pharmacist’s critical role in patient education, adherence support, and bridging clinical evidence with real-world care.
Redefining Collaboration in Clinical Trials: How Sponsors, CROs, and Sites Can Align
In an interview with Applied Clinical Trials, Jim Kremidas, executive director, Association for MultiSite Research Corporations, emphasized that improved communication, standardized training, and shared risk models between sponsors, CROs, and clinical sites are essential to enhancing collaboration, efficiency, and quality in clinical trial execution.
Vaccine Stocks Muted as Investors Assess Kennedy's Overhaul of Key Panel
Vaccine stocks were largely unchanged after HHS Secretary Robert F. Kennedy Jr. unexpectedly dismissed all members of a key vaccine advisory panel, signaling increased regulatory uncertainty that investors had largely anticipated.
